Zobrazeno 1 - 10 of 1 689 pro vyhledávání: '"Sofen H"'
1
Akademický článek
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.
Autor: Korman NJ; Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Bagel J; Psoriasis Treatment Center of New Jersey, East Windsor, NJ, USA., Armstrong AW; University of California Los Angeles, Los Angeles, CA, USA., Gooderham M; SKiN Centre for Dermatology, Peterborough, Queen's University, Kingston, and Probity Medical Research, Waterloo, ON, Canada., Strober B; Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USA., Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany., Morita A; Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan., Imafuku S; Faculty of Medicine, Fukuoka University Hospital, Fukuoka, Japan., Foley P; The University of Melbourne, Parkville, St. Vincent's Hospital Melbourne, Fitzroy, and Probity Medical Research and Skin Health Institute, Carlton, VIC, Australia., Sofen H; University of California Los Angeles, Los Angeles, CA, USA.; Dermatology Research Associates, Los Angeles, CA, USA., Zheng M; The Second Affiliated Hospital and Zhejiang University School of Medicine, Hangzhou, China., Hippeli L; Bristol Myers Squibb, Princeton, NJ, USA., Kisa RM; Bristol Myers Squibb, Princeton, NJ, USA., Banerjee S; Bristol Myers Squibb, Princeton, NJ, USA., Blauvelt A; Oregon Medical Research Center, Portland, OR, USA.
Publikováno v: The Journal of dermatological treatment [J Dermatolog Treat] 2024 Dec; Vol. 35 (1), pp. 2371045. Date of Electronic Publication: 2024 Jun 30.
Zobrazit plný text záznamu
2
Akademický článek
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.
Autor: Lio PA; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. peterlio@gmail.com.; Medical Dermatology Associates of Chicago, Chicago, IL, USA. peterlio@gmail.com., Armstrong A; Keck School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.; Clinical Research for the Southern California Clinical and Translational Research Institute (SC CTSI), Los Angeles, CA, USA., Gutermuth J; Department of Dermatology, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Jette, Belgium., Nosbaum A; Service d'Allergologie et Immunologie Clinique, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France., Sofen H; Department of Dermatology, School of Medicine, University of California, Los Angeles, CA, USA., Gil EG; Almirall, Barcelona, Spain., Casillas M; Eli Lilly and Company, Indianapolis, USA., Chen S; Tigermed, Somerset, NJ, USA., Sun L; Eli Lilly and Company, Indianapolis, USA., Pierce E; Eli Lilly and Company, Indianapolis, USA., Elmaraghy H; Eli Lilly and Company, Indianapolis, USA., Dawson Z; Eli Lilly and Company, Indianapolis, USA., Torres T; Department of Dermatology, Centro Hospitalar Universitario de Santo António, ICBAS, University of Porto, Porto, Portugal.
Publikováno v: Dermatology and therapy [Dermatol Ther (Heidelb)] 2024 Jul; Vol. 14 (7), pp. 1929-1943. Date of Electronic Publication: 2024 Jun 26.
Zobrazit plný text záznamu
4
Akademický článek
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Autor: Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Warren RB; Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK., Sofen H; University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Imafuku S; Fukuoka University Hospital, Fukuoka, Japan., Paul C; Toulouse University and CHU, Toulouse, France., Szepietowski JC; Wroclaw Medical University, Wroclaw, Poland., Spelman L; Veracity Clinical Research, Brisbane, QLD, Australia., Passeron T; Université Côte d'Azur, University Hospital of Nice, Nice, France., Vritzali E; Bristol Myers Squibb, Princeton, NJ, USA., Napoli A; Bristol Myers Squibb, Princeton, NJ, USA., Kisa RM; Bristol Myers Squibb, Princeton, NJ, USA., Buck A; Cytel Inc, Waltham, MA, USA., Banerjee S; Bristol Myers Squibb, Princeton, NJ, USA., Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany., Blauvelt A; Oregon Medical Research Center, Portland, OR, USA.
Publikováno v: The British journal of dermatology [Br J Dermatol] 2024 Apr 17; Vol. 190 (5), pp. 668-679.
Zobrazit plný text záznamu
5
Akademický článek
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Autor: Blauvelt A; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com., Rich P; Oregon Dermatology and Research Center, Portland, Oregon., Sofen H; Division of Dermatology, UCLA School of Medicine, Dermatology Research Associates, Los Angeles, California., Strober B; Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut; Central Connecticut Dermatology Research, Cromwell, Connecticut., Merola JF; Department of Dermatology, Brigham and Women's Hospital, Brigham Dermatology Associates, Boston, Massachusetts; Department of Dermatology, Harvard Medical School, Boston, Massachusetts., Lebwohl M; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York., Morita A; Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan., Szepietowski JC; Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Wrocław, Poland., Lambert J; Department of Dermatology, Ghent University, Ghent, Belgium., Hippeli L; Bristol Myers Squibb, Princeton, New Jersey., Colston E; Bristol Myers Squibb, Princeton, New Jersey., Balagula E; Bristol Myers Squibb, Princeton, New Jersey., Banerjee S; Bristol Myers Squibb, Princeton, New Jersey., Thaçi D; Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Apr; Vol. 90 (4), pp. 775-782. Date of Electronic Publication: 2023 Dec 18.
Zobrazit plný text záznamu
6
Akademický článek
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis.
Autor: Mohamed MF; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., Qian Y; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., D'Cunha R; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., Sligh T; Velocity Clinical Research, North Hollywood, California, USA., Ferris LK; Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Eldred A; Immunology Development, AbbVie Inc., North Chicago, Illinois, USA., Levy GF; Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, Illinois, USA., Hao S; Discovery and Exploratory Statistics, AbbVie Inc., North Chicago, Illinois, USA., Gannu S; Regulated Bioanalysis, AbbVie Inc., North Chicago, Illinois, USA., Rizzo DG; Regulated Bioanalysis, AbbVie Inc., North Chicago, Illinois, USA., Liu W; Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA., Jazayeri S; Alliance Dermatology and Mohs Center, Phoenix, Arizona, USA., Sofen H; University of California Los Angeles School of Medicine and Dermatology Research Associates, Los Angeles, California, USA., Carcereri De Prati R; Immunology Development, AbbVie, Ludwigshafen, Germany.
Publikováno v: Clinical and translational science [Clin Transl Sci] 2024 Jan; Vol. 17 (1), pp. e13682. Date of Electronic Publication: 2023 Dec 19.
Zobrazit plný text záznamu
7
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
Autor: Warren, RB, Lebwohl, M, Sofen, H, Piguet, V, Augustin, M, Brock, F, C Arendt, Fierens, F, Blauvelt, A
Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV, vol 35, iss 12
BackgroundCertolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumor necrosis factor biologic.ObjectivesTo report 3-year outcomes from the CIMPACT (NCT02346240) phase 3, CZP in moderate to severe plaque psoriasis, randomized controlled trial.Method
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::ef086d788a4cf4b047b27ffd2b4b173c
https://escholarship.org/uc/item/60q8t66g
Zobrazit plný text záznamu
8
Akademický článek
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Autor: Strober B; Department of Dermatology, Yale University School of Medicine, New Haven, & Central Connecticut Dermatology Research, Cromwell, CT, USA., Thaçi D; Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany., Sofen H; Department of Dermatology & Pediatrics, UCLA School of Medicine, Los Angeles, CA, USA., Kircik L; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Gordon KB; Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA., Foley P; Department of Dermatology, The University of Melbourne, Skin Health Institute & Probity Medical Research, Carlton, VIC, Australia., Rich P; Oregon Dermatology & Research Center, Portland, OR, USA., Paul C; University of Toulouse & CHU, Toulouse, France., Bagel J; Psoriasis Treatment Center of New Jersey, East Windsor, NJ, USA., Colston E; Bristol Myers Squibb, Princeton, NJ, USA., Throup J; Bristol Myers Squibb, Princeton, NJ, USA., Kundu S; Bristol Myers Squibb, Princeton, NJ, USA., Sekaran C; Bristol Myers Squibb, Princeton, NJ, USA., Linaberry M; Bristol Myers Squibb, Princeton, NJ, USA., Banerjee S; Bristol Myers Squibb, Princeton, NJ, USA., Papp KA; Alliance Clinical Trials & Probity Medical Research, Waterloo, ON, Canada.
Publikováno v: Immunotherapy [Immunotherapy] 2023 Aug; Vol. 15 (11), pp. 787-797. Date of Electronic Publication: 2023 May 07.
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Autor: Langley RG; Dalhousie University, Halifax, NS, Canada., Sofen H; Department of Medicine (Dermatology) UCLA, Los Angeles, CA, USA., Dei-Cas I; Facultad de Medicina de la Universidad de Buenos Aires, Buenos Aires, Argentina., Reich K; Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Sigurgeirsson B; University of Iceland, Reykjavik, Iceland., Warren RB; Centre for Dermatology Research, University of Manchester, Manchester, UK.; Salford Royal NHS Foundation Trust, Manchester, UK., Paul C; Department of Dermatology, Paul Sabatier University, Toulouse, France., Szepietowski JC; Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland., Tsai TF; National Taiwan University Hospital, Taipei, Taiwan., Hampele I; Novartis Pharma AG, Basel, Switzerland., You R; China Novartis Institutes for BioMedical Research, Shanghai, China., Charef P; Novartis Pharma AG, Basel, Switzerland., Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
Publikováno v: The British journal of dermatology [Br J Dermatol] 2023 Feb 10; Vol. 188 (2), pp. 198-207.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje